2. Acetylcysteine group (NAC+S) , aside with the saline, patients will be given orally Acetylcysteine at a dose of 600 mg twice daily, on the day before and on the day of administration of the contrast agent.

Carnitine group (Car+S), aside with the saline, patients will be administrated with 20 mg/kg carnitine over 10 minutes 2 hours prior to the administration of the contrast agent and 8 hours after CT.

4. Phosphodiesterase type 5 inhibitor group (PDE5+S), aside with the saline patients will be given orally 20 mg tablets of PDE5 Tadalafil once daily 2 hours prior to the administration of the contrast agent and in the subsequent day.

Control group ( S ) , which will be treated without any extra agents, just Saline (0.9 %) will be given I.V. at a rate of 1 ml per kilogram of body weight per hour for 12 hours before and 12 hours after administration of the contrast agent.

Contrast Media Induced Nephropathy

to evaluate the effect of the above agents on Kidney functioning parameters

Acetylcysteine, Phosphodiesterase type 5 inhibitor ,Carnitine

Nazreth Hospital

Nephroprotective Effects of Carnitine and (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN)

Potentially Nephroprotective Effects of Carnitine and Phosphodiesterase Type 5 (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN): A Double Blind Randomized Study

The Nazareth Hospital

Zaher Armaly M.D. , Head of Nephrology Department

Western Galilee Hospital-Nahariya

Tablet Tadalafil 20 mg every alternate day

Lung Diseases, Interstitial

Tab. Tadalafil 20 mg every other day for 6 months

Tadalafil

Shape , size, color and odor matched Tab. of inert material every other day for 6 months

Placebo

SGPGIMS

A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma

A Double Blind Randomized Control Trial of Tadalafil in Interstitial Lung Disease of Scleroderma

To assess the change in FVC (expressed as a percentage of the predicted value) from baseline values at the end of 6 months

To assess the improvement in dyspnoea (as measured by Mehler dyspnoea index) at the end of 6 month

To assess improvement in 6 min walk test at the end of 6 months

To assess the change in DLCO from baseline values at the end of 6 months

To assess the change in total lung capacity from baseline values at the end of 6 months

To assess the change in the disability index of the Health Assessment Questionnaire (S HAQ) at 6 months from baseline

To assess the change in the Medical Outcomes Study 36-item Short-Form General Health Survey (SF-36) from baseline to end of 6 months

guanosine/diarrhea

Nephroprotective Effects of Carnitine and (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN)

A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma

The most complete medicinal herbs database backed by science